Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review.

INTRODUCTION Epithelioid hemangioendothelioma (EHE) is a family of blood vessel tumors originating in blood vessels, bone, brain, kidney, liver, and lung. EHE is more common in women, and chemotherapy, radiation, and surgery have brought few successes. CASE PRESENTATION We present a case of a 28-year-old woman whose EHE recurred during pregnancy, suggesting hormonal involvement. We conducted a systematic review to provide analysis and interpretation of the potential significance of her disease recurring, with fatal outcome, during pregnancy. DISCUSSION Very little research has explored the use of individual hormonal markers. Strongly positive expression of placenta growth factor (PlGF) and 17-beta estradiol receptors have been reported. Expression of PlGF is noteworthy in our case, in that our patient's disease quickly and dramatically flared in the 25th week of pregnancy, near the peak in maternal PlGF production. PlGF binds to vascular endothelial growth factor-1 (VEGF-1), and PlGF may accelerate VEGF-induced angiogenesis. Taken together, these factors may explain our patient's EHE recurrence and rapid flare-up during pregnancy. Treatment of EHE with VEGF inhibition, potentially in combination with other antiangiogenic and tumor-inhibiting therapies such as lenalidomide, thalidomide, sorafenib, and sunitinib, may also hold promise.

[1]  S. Curley,et al.  Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[2]  R. Groeschl,et al.  Does histology predict outcome for malignant vascular tumors of the liver? , 2014, Journal of surgical oncology.

[3]  M. Bernaudin,et al.  Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. , 2014, Investigative ophthalmology & visual science.

[4]  D. Moher,et al.  The CARE Guidelines: Consensus-based Clinical Case Report Guideline Development , 2013, Journal of dietary supplements.

[5]  C. Zuo,et al.  MRI and FDG PET/CT Findings of Hepatic Epithelioid Hemangioendothelioma , 2013, Clinical nuclear medicine.

[6]  H. Nishino,et al.  Case of high‐risk epithelioid hemangioendothelioma of the neck , 2012, Head & neck.

[7]  Q. Ye,et al.  Clinical Experience with Primary Hepatic Epithelioid Hemangioendothelioma: Retrospective Study of 33 Patients , 2012, World Journal of Surgery.

[8]  P. C. Rocha Oliveira,et al.  Cerebral epithelioid hemangioendothelioma with thoracic simultaneous involvement: advanced MRI features. , 2012, Arquivos de neuro-psiquiatria.

[9]  I. Shelef,et al.  Increased echogenicity of the interhemispheric sulcus: a potential diagnostic pitfall on cranial ultrasound of the newborn. , 2012, The Israel Medical Association journal : IMAJ.

[10]  E. Lerut,et al.  Epithelioid Hemangioendothelioma of the Kidney Treated with Sunitinib , 2012, Oncology Research and Treatment.

[11]  B. Sangro,et al.  Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib , 2012, Rare tumors.

[12]  T. Kashiwagi,et al.  Primary epithelioid hemangioendothelioma of the retroperitoneum: report of a case , 2012, Surgery Today.

[13]  I. Swainson,et al.  Serial bone scintigraphy in a case of malignant epithelioid hemangioendothelioma. , 2012, Clinical nuclear medicine.

[14]  V. Sondhi,et al.  Successful management of multi-focal hepatic infantile hemangioendothelioma using TACE/surgery followed by maintenance metronomic therapy , 2012, BMJ Case Reports.

[15]  Joannie T. Yeh,et al.  Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. , 2011, Chest.

[16]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[17]  K. Shomori,et al.  Pulmonary Epithelioid Hemangioendothelioma with PlGF Expression: Report of a Case , 2011, The Thoracic and cardiovascular surgeon.

[18]  J. Lester,et al.  Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report , 2010, Journal of medical case reports.

[19]  V. Ravi,et al.  Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor , 2010, Current opinion in oncology.

[20]  G. Sevlever,et al.  VEGF and CD31 Association in Pituitary Adenomas , 2010, Endocrine pathology.

[21]  Yuan Ji,et al.  CT and MRI diagnosis of hepatic epithelioid hemangioendothelioma. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[22]  R. Fredericks,et al.  Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease , 2010, Journal of Neuro-Oncology.

[23]  W. Budach,et al.  Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon. , 2006, European journal of medical research.

[24]  K. Das,et al.  A translocation involving the placental growth factor gene is identified in an epithelioid hemangioendothelioma. , 2006, Cancer genetics and cytogenetics.

[25]  Li Tao,et al.  [Correlation between the expression of VEGF-C mRNA, VEGFR-3, CD31 and tumor metastases in Chinese with prostate cancer]. , 2005, Shi yan sheng wu xue bao.

[26]  D. V. van Thiel,et al.  Thalidomide Inhibits the Growth and Progression of Hepatic Epithelioid Hemangioendothelioma , 2005, Oncology.

[27]  B. Vincenzi,et al.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer , 2004, Journal of Clinical Pathology.

[28]  K. Arihiro,et al.  Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis , 1998, Breast cancer.

[29]  W. Laskin,et al.  Epithelioid hemangioendothelioma with multiple site involvement. Literature review and observations , 1994, Cancer.

[30]  T. Colby,et al.  Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. , 1991, American journal of clinical pathology.

[31]  Katherine M Enzinger,et al.  Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. , 1982, Cancer.

[32]  R. Doebele,et al.  Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer , 2013 .

[33]  J. Živný,et al.  In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1. , 2013, Folia biologica.

[34]  C. Antonescu,et al.  Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. , 2012, Cancer genetics.

[35]  T. Tominaga,et al.  A case of intravascular epithelioid hemangioendothelioma occurring 14 years after coil embolization for an extracranial internal carotid artery aneurysm. , 2012, Journal of vascular surgery.

[36]  Li-xin Zhou,et al.  [Hepatic epithelioid hemangioendothelioma in needle biopsy specimens: report of 5 cases with review of literature]. , 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[37]  B. Nervi,et al.  Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. , 2011, Annals of hepatology.

[38]  D. Yılmazer,et al.  A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma , 2006, International Urology and Nephrology.

[39]  W. Papierz,et al.  The morphological analysis of vasculature and angiogenic potential in meningiomas: immunoexpression of CD31 and VEGF antibodies. , 2003, Folia neuropathologica.